American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

Mekinian, A; Georgin-Lavialle, S; Ferrada, MA; Savic, S; Koster, MJ; Kosmider, O; Comont, T; Heiblig, M; Arostegui, JI; Bosco, A; Bourguiba, R; Calvo, KR; Cargo, C; Cattaneo, C; Chasset, F; Coelho, H; Campochiaro, C; Crisafulli, F; Ducharme-Benard, S; Faria, R; Franceschini, F; Frassi, M; Groarke, EM; Gurnari, C; Hakobyan, Y; Jamilloux, Y; Jurcut, C; Kirino, Y; Kulasekararaj, A; Kunimoto, H; Madigan, LM; Mann, HF; Marvisi, C; Milchert, M; Morais, S; Sockel, K; Muratore, F; Nakajima, H; Patnaik, MM; Regadas, L; Robin, M; Rutgers, A; Salvarani, C; Sammel, AM; Seebach, J; Sujobert, P; Tomelleri, A; Urbanski, G; Vandergheynst, F; Vieira, R; Viswanatha, DS; Więsik-Szewczyk, E; Diral, E; Terrier, B; Patel, BA; Fenaux, P; Grayson, PC; Beck, DB; International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases

doi:10.1002/art.43287

Autoinflammatory & rare systemic diseases

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

Arthritis RheumatolPublished 11 Aug 2025Guidance statement

Read the original article ↗PubMed

Cite

Methodological detailsinternational expert consensus, international multidisciplinary expert panel, formalized meetings and voting process

International expert consensus
International multidisciplinary expert panel
Formalized meetings and voting process

Recommendations

As issued by the authors

Clinical features of VEXAS
UBA1 screening methods
Diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS
Prognosis and management

Reference

Issued by: ACR; International VEXAS Working Group Expert Panel
Document: Consensus clinical guidance statement
Scope: Diagnosis and management of VEXAS: which patients to test, how to test, approach to MDS in VEXAS, management

Authors: Mekinian A, Georgin-Lavialle S, Ferrada MA, Savic S, Koster MJ, Kosmider O, et al.
All 59 authors
Mekinian A, Georgin-Lavialle S, Ferrada MA, Savic S, Koster MJ, Kosmider O, Comont T, Heiblig M, Arostegui JI, Bosco A, Bourguiba R, Calvo KR, Cargo C, Cattaneo C, Chasset F, Coelho H, Campochiaro C, Crisafulli F, Ducharme-Benard S, Faria R, Franceschini F, Frassi M, Groarke EM, Gurnari C, Hakobyan Y, Jamilloux Y, Jurcut C, Kirino Y, Kulasekararaj A, Kunimoto H, Madigan LM, Mann HF, Marvisi C, Milchert M, Morais S, Sockel K, Muratore F, Nakajima H, Patnaik MM, Regadas L, Robin M, Rutgers A, Salvarani C, Sammel AM, Seebach J, Sujobert P, Tomelleri A, Urbanski G, Vandergheynst F, Vieira R, Viswanatha DS, Więsik-Szewczyk E, Diral E, Terrier B, Patel BA, Fenaux P, Grayson PC, Beck DB, International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases
Journal: Arthritis & Rheumatology
Published: 11 Aug 2025
DOI: 10.1002/art.43287
PubMed: 40787890

Topic: Autoinflammatory & rare systemic diseases

Original publication

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel. Arthritis Rheumatol. Published 11 August 2025. doi:10.1002/art.43287

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →